APA (7th ed.) Citation

GA, B., RM, E., & MN, F. (2026). Immunometabolic reprogramming in multiple sclerosis: From pathogenic amplifier to therapeutic target in neuroinflammation and remyelination. Inflammopharmacology. https://doi.org/10.1007/s10787-026-02350-y

Chicago Style (17th ed.) Citation

GA, Badawi, El-Sayed RM, and Fawzy MN. "Immunometabolic Reprogramming in Multiple Sclerosis: From Pathogenic Amplifier to Therapeutic Target in Neuroinflammation and Remyelination." Inflammopharmacology 2026. https://doi.org/10.1007/s10787-026-02350-y.

MLA (9th ed.) Citation

GA, Badawi, et al. "Immunometabolic Reprogramming in Multiple Sclerosis: From Pathogenic Amplifier to Therapeutic Target in Neuroinflammation and Remyelination." Inflammopharmacology, 2026, https://doi.org/10.1007/s10787-026-02350-y.